GSK is investing $2 million in research to address ongoing, new, and emerging threats to lung health in Canada. The funds will be managed and administered by the Canadian Institutes of Health Research (CIHR) through the Team Grants in Lung Health initiative. GSK's contribution is the largest private financial contribution to this research initiative to date.
/CNW/ - GSK has filed a New Drug Submission (NDS) to Health Canada for its respiratory syncytial virus (RSV) older adult vaccine candidate. If approved, GSK s.
GSK announced today that it has been granted Notice of Compliance with conditions for its endometrial cancer treatment JEMPERLI (dostarlimab for injection) by Health Canada. - Click here if this is your press release! - eTurboNews | Trends | Travel News
GlaxoSmithKline Inc. today announced that SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) has been approved in Canada for the prevention of shingles (herpes